Targeting platelet thrombin receptor signaling to prevent thrombosis

Eric L. Wallace, Susan S. Smyth

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.

Original languageEnglish
Pages (from-to)915-928
Number of pages14
JournalPharmaceuticals
Volume6
Issue number8
DOIs
StatePublished - Feb 8 2013

Keywords

  • Platelets
  • Protease-activated receptors
  • Thrombin
  • Thrombosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Targeting platelet thrombin receptor signaling to prevent thrombosis'. Together they form a unique fingerprint.

Cite this